Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics (NQ: ABEO )

2.390 +0.090 (+3.91%)
Streaming Delayed Price Updated: 10:15 AM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,086
Open 2.390
Bid (Size) 2.340 (1)
Ask (Size) 2.400 (9)
Prev. Close 2.300
Today's Range 2.330 - 2.430
52wk Range 2.190 - 9.355
Shares Outstanding 17,175,799
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting
From Abeona Therapeutics Inc.
Via Globe NewsWire
Abeona Therapeutics Announces Update on AAV Ophthalmology Program
From Abeona Therapeutics Inc.
Via Globe NewsWire

Performance

YTD
-16.43%
-16.43%
1 Month
+1.70%
+1.70%
3 Month
-5.91%
-5.91%
6 Month
-38.08%
-38.08%
1 Year
-66.84%
-66.84%

More News

Read More
Three Small-Cap Biotech Stocks to Consider Now
Via MarketBeat
PXMD, GETY: The Top 5 Short Squeeze Stocks to Watch This Week
Via InvestorPlace
Cantor Bullish On Abeona Saying Recent Trial Data 'Best Case Scenario'
Via Benzinga
Abeona Therapeutics Touts Positive Data From Pivotal EB-101 Study In Blistering Skin Disorder
Via Benzinga
PaxMedica, Getty Images And 3 Short Squeeze Candidates That Could Soar This Week
Via Benzinga
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
From Abeona Therapeutics Inc.
Via Globe NewsWire
Abeona Therapeutics Announces $35 Million Private Placement Financing
From Abeona Therapeutics Inc.
Via Globe NewsWire
Recap: Abeona Therapeutics Q2 Earnings
Via Benzinga
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
From Abeona Therapeutics Inc.
Via Globe NewsWire
Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From Abeona Therapeutics Inc.
Via Globe NewsWire
How Is The Market Feeling About Abeona Therapeutics?
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Via Benzinga
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
From Abeona Therapeutics Inc.
Via Globe NewsWire
Why NVIDIA, Microsoft And Amazon Shares Traded Lower; Here Are 73 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Aehr Test Systems Shares Are Trading Higher By Over 19%, Here Are 51 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Via Benzinga
Tesla, Twitter And 76 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.